Oxamflatin

Drug Profile

Oxamflatin

Latest Information Update: 30 Jun 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi
  • Class Antineoplastics; Hydroxamic acids
  • Mechanism of Action Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Jun 1998 Discontinued-Preclinical for Cancer in Japan (Unknown route)
  • 02 Oct 1996 Preclinical development for Cancer in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top